Infectious Diseases Search
Infectious Diseases Infectious Diseases
genital%20herpes
GENITAL HERPES
Genital herpes is a recurrent lifelong disease with no cure, caused by herpes simplex virus (HSV).
HSV-2 is usually the cause but HSV-1 may occur in up to 1/3 of new cases.
HSV-1 tends to cause fewer recurrences & milder disease than HSV-2.
The incubation period is 2 days-2 weeks after exposure.

Genital%20herpes Signs and Symptoms

Introduction

  • Recurrent lifelong disease with no cure, caused by herpes simplex virus (HSV)
  • Typically occurs in adults, usually transmitted through sexual contact 
  • Incubation period is 2 days-2 weeks after exposure

Etiology

Herpes Simplex Virus (HSV)
  • HSV-1: Tends to cause fewer recurrences and milder disease than HSV-2
  • HSV-2: Usually the cause of genital herpes but HSV-1 may occur in up to 1/3 of new cases

Risk Factors

Risk Factors for Genital Herpes Simplex Virus Infection
  • Multiple sexual partners
  • Previous history of sexually transmitted infection (STI) including HIV
  • History of genital lesion in self or partner
  • Partner diagnosed with genital HSV infection
  • Early age of 1st sexual activity (≤17 years old)
  • Female gender
  • Low socioeconomic status; low level of education
  • Advancing age
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
COVID-19 pandemic causes drop in cardiovascular diagnostic testing
2 days ago
Diagnosis of heart diseases has abruptly and significantly decreased across the globe due to the coronavirus disease 2019 (COVID-19) pandemic, especially affecting poorer countries, reveals a study.
Pfizer and BioNTech are testing 4 novel vaccines in Europe and US.
Pank Jit Sin, 13 May 2020
A trial vaccine for the prevention of COVID-19 is underway with the first US participants being dosed in the Phase 1/2 clinical trial. Known as the BNT162 vaccine programme, the trials are a collaboration between Pfizer Inc. and BioNTech SE, and is part of a global development programme with Germany and the US taking the lead in having the first cohorts to be vaccinated. Germany started the study 1 week earlier.